1
|
Kannel WB, Wolf PA, Benjamin EJ and Levy
D: Prevalence, incidence, prognosis, and predisposing conditions
for atrial fibrillation: Population-based estimates. Am J Cardiol
82 (8A). 2N–9N. 1998. View Article : Google Scholar
|
2
|
Feinberg WM, Blackshear JL, Laupacis A,
Kronmal R and Hart RG: Prevalence, age distribution, and gender of
patients with atrial fibrillation. Analysis and implications. Arch
Intern Med. 155:469–473. 1995. View Article : Google Scholar : PubMed/NCBI
|
3
|
Benjamin EJ, Wolf PA, D'Agostino RB,
Silbershatz H, Kannel WB and Levy D: Impact of atrial fibrillation
on the risk of death: The Framingham Heart Study. Circulation.
98:946–952. 1998. View Article : Google Scholar : PubMed/NCBI
|
4
|
Anter E, Jessup M and Callans DJ: Atrial
fibrillation and heart failure: Treatment considerations for a dual
epidemic. Circulation. 119:2516–2525. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Hoppe UC, Casares JM, Eiskjaer H, Hagemann
A, Cleland JGF, Freemantle N and Erdmann E: Effect of cardiac
resynchronization on the incidence of atrial fibrillation in
patients with severe heart failure. Circulation. 114:18–25. 2006.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Gazewood JD and Turner PL: Heart Failure
with Preserved Ejection Fraction: Diagnosis and Management. Am Fam
Physician. 96:582–588. 2017.PubMed/NCBI
|
7
|
Kirchhof P, Benussi S, Kotecha D, Ahlsson
A, Atar D, Casadei B, Castellá M, Diener HC, Heidbuchel H, Hendriks
J, et al: 2016 ESC Guidelines for the Management of Atrial
Fibrillation Developed in Collaboration With EACTS. Rev Esp Cardiol
(Engl Ed). 70:502017.PubMed/NCBI
|
8
|
Swedberg K, Olsson LG, Charlesworth A,
Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C and
Poole-Wilson P: Prognostic relevance of atrial fibrillation in
patients with chronic heart failure on long-term treatment with
beta-blockers: Results from COMET. Eur Heart J. 26:1303–1308. 2005.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Pedersen OD, Bagger H, Kober L and
Torp-Pedersen C: Trandolapril reduces the incidence of atrial
fibrillation after acute myocardial infarction in patients with
left ventricular dysfunction. Circulation. 100:376–380. 1999.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Ducharme A, Swedberg K, Pfeffer MA,
Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ,
Olsson L, Rouleau JL, et al CHARM Investigators, : Prevention of
atrial fibrillation in patients with symptomatic chronic heart
failure by candesartan in the Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity (CHARM) program.
Am Heart J. 152:86–92. 2006. View Article : Google Scholar : PubMed/NCBI
|
11
|
McMurray J, Køber L, Robertson M, Dargie
H, Colucci W, Lopez-Sendon J, Remme W, Sharpe DN and Ford I:
Antiarrhythmic effect of carvedilol after acute myocardial
infarction: Results of the Carvedilol Post-Infarct Survival Control
in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll
Cardiol. 45:525–530. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kotecha D, Holmes J, Krum H, Altman DG,
Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P,
et al Beta-Blockers in Heart Failure Collaborative Group, :
Efficacy of β blockers in patients with heart failure plus atrial
fibrillation: An individual-patient data meta-analysis. Lancet.
384:2235–2243. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Piccini JP, Connolly SJ, Abraham WT,
Healey JS, Steinberg BA, Al-Khalidi HR, Dignacco P, van Veldhuisen
DJ, Sauer WH, White M, et al: A genotype-directed comparative
effectiveness trial of Bucindolol and metoprolol succinate for
prevention of symptomatic atrial fibrillation/atrial flutter in
patients with heart failure: Rationale and design of the GENETIC-AF
trial. Am Heart J. 199:51–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
14
|
Silvet H, Hawkins LA and Jacobson AK:
Heart rate control in patients with chronic atrial fibrillation and
heart failure. Congest Heart Fail. 19:25–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Dolgin Martin: Nomenclature and criteria
for diagnosis of diseases of the heart and great vessels/the
Criteria Committee of the New York Heart Association. 9th. Little
Brown; Boston: 1994
|
16
|
ATS Committee on Proficiency Standards for
Clinical Pulmonary Function Laboratories, . ATS statement:
Guidelines for the six-minute walk test. Am J Respir Crit Care Med.
166:111–117. 2002. View Article : Google Scholar : PubMed/NCBI
|
17
|
Bristow MR: Treatment of chronic heart
failure with β-adrenergic receptor antagonists: A convergence of
receptor pharmacology and clinical cardiology. Circ Res.
109:1176–1194. 2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
McMurray JJV, Adamopoulos S, Anker SD,
Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C,
Gomez-Sanchez MA, et al Task Force for the Diagnosis and Treatment
of Acute and Chronic Heart Failure 2012 of the European Society of
Cardiology; ESC Committee for Practice Guidelines, : ESC guidelines
for the diagnosis and treatment of acute and chronic heart failure
2012: The Task Force for the Diagnosis and Treatment of Acute and
Chronic Heart Failure 2012 of the European Society of Cardiology.
Developed in collaboration with the Heart Failure Association (HFA)
of the ESC. Eur J Heart Fail. 14:803–869. 2012. View Article : Google Scholar : PubMed/NCBI
|
19
|
Hunt SA, Abraham WT, Chin MH, Feldman AM,
Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K,
et al American College of Cardiology Foundation; American Heart
Association, : 2009 Focused update incorporated into the ACC/AHA
2005 Guidelines for the Diagnosis and Management of Heart Failure
in Adults A Report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines Developed in Collaboration With the International
Society for Heart and Lung Transplantation. J Am Coll Cardiol.
53:e1–e90. 2009. View Article : Google Scholar : PubMed/NCBI
|
20
|
Lindenfeld J, Albert NM, Boehmer JP,
Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser
DK, Rogers JG, et al Heart Failure Society of America, : HFSA 2010
Comprehensive Heart Failure Practice Guideline. J Card Fail.
16:e1–e194. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Miller RJH, Howlett JG, Chiu MH, Southern
DA, Knudtson M and Wilton SB: Relationships among achieved heart
rate, β-blocker dose and long-term outcomes in patients with heart
failure with atrial fibrillation. Open Heart. 3:e0005202016.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Chatterjee S, Biondi-Zoccai G, Abbate A,
D'Ascenzo F, Castagno D, Van Tassell B, Mukherjee D and Lichstein
E: Benefits of β blockers in patients with heart failure and
reduced ejection fraction: Network meta-analysis. BMJ 346 (jan16
1). f552013.
|
23
|
Edelmann F, Musial-Bright L, Gelbrich G,
Trippel T, Radenovic S, Wachter R, Inkrot S, Loncar G, Tahirovic E,
Celic V, et al CIBIS-ELD Investigators and Project Multicenter
Trials in the Competence Network Heart Failure, : Tolerability and
Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF:
Insights From the CIBIS-ELD Trial. JACC Heart Fail. 4:140–149.
2016. View Article : Google Scholar : PubMed/NCBI
|
24
|
Yamamoto K, Origasa H and Hori M; J-DHF
Investigators, : Effects of carvedilol on heart failure with
preserved ejection fraction: The Japanese Diastolic Heart Failure
Study (J-DHF). Eur J Heart Fail. 15:110–118. 2013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Flather MD, Shibata MC, Coats AJS, Van
Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu
D, Ferrari R, Lechat P, et al SENIORS Investigators, : Randomized
trial to determine the effect of nebivolol on mortality and
cardiovascular hospital admission in elderly patients with heart
failure (SENIORS). Eur Heart J. 26:215–225. 2005. View Article : Google Scholar : PubMed/NCBI
|
26
|
Mittal N, Shafiq N, Reddy S, Malhotra S,
Kumari S and Varma S: Evaluation of efficacy of metoprolol in
patients having heart failure with preserved ejection fraction: A
randomized, double-blind, placebo-controlled pilot trial. Perspect
Clin Res. 8:124–131. 2017.PubMed/NCBI
|
27
|
Hernandez AF, Hammill BG, O'Connor CM,
Schulman KA, Curtis LH and Fonarow GC: Clinical effectiveness of
beta-blockers in heart failure: Findings from the OPTIMIZE-HF
(Organized Program to Initiate Lifesaving Treatment in Hospitalized
Patients with Heart Failure) Registry. J Am Coll Cardiol.
53:184–192. 2009. View Article : Google Scholar : PubMed/NCBI
|